RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hangzhou Tigermed Consulting Co Stock

Hangzhou Tigermed Consulting Co Equity 2024

Hangzhou Tigermed Consulting Co Equity

21.03 B CNY

Ticker

300347.SZ

ISIN

CNE100001KV8

In 2024, Hangzhou Tigermed Consulting Co's equity was 21.03 B CNY, a 7.37% increase from the 19.58 B CNY equity in the previous year.

Hangzhou Tigermed Consulting Co Aktienanalyse

What does Hangzhou Tigermed Consulting Co do?

Hangzhou Tigermed Consulting Co Ltd is a leading Chinese company in the field of clinical research and medical services. The company was founded in Hangzhou in 2004 and has since experienced rapid development. Today, the company has branches in over 20 countries and employs over 11,000 people worldwide. Hangzhou Tigermed's business model is based on supporting the entire value chain of clinical trials, from planning and execution to statistical analysis and data interpretation. The company works closely with global actors from the pharmaceutical industry, biomedical research institutions, and regulatory authorities to meet international standards for clinical studies. Over the years, Hangzhou Tigermed has expanded its business activities to include various areas such as data management, biostatistics, medical translation, clinical monitoring, drug safety monitoring, and traceability. An important part of Hangzhou Tigermed's business model is the ability to use high-tech platforms and IT systems to enable real-time monitoring and communication during a clinical trial. This allows the company to quickly respond to adverse events and monitor the progress of the study in real-time. The company also offers specialized services, such as the evaluation of oncology studies and the conduct of studies in the field of traditional Chinese medicine. In addition, Hangzhou Tigermed also has its own pharmaceutical research department specializing in the development of innovative drugs. The company has built strong research and development capabilities, with a focus on open innovation projects and partnerships with research institutions and pharmaceutical companies. In collaboration with its industry partners, Hangzhou Tigermed has conducted a number of research projects that have led to significant innovations in medicine. Hangzhou Tigermed also has a strong presence in the international market, particularly in North America and Europe. Through its branches in these regions, the company is able to offer comprehensive collaboration to its customers on a global level. Overall, Hangzhou Tigermed Consulting Co Ltd has established itself as a significant force in the clinical research industry. The company has developed a wide range of services to meet the needs of its customers in the industry. Hangzhou Tigermed's ability to work closely with its customers and adhere to global standards has helped it become a preferred partner for clinical studies and innovative research projects worldwide. Hangzhou Tigermed Consulting Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Hangzhou Tigermed Consulting Co's Equity

Hangzhou Tigermed Consulting Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Hangzhou Tigermed Consulting Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Hangzhou Tigermed Consulting Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Hangzhou Tigermed Consulting Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Hangzhou Tigermed Consulting Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Hangzhou Tigermed Consulting Co stock

What is the equity of Hangzhou Tigermed Consulting Co this year?

Hangzhou Tigermed Consulting Co has equity of 21.03 B CNY this year.

What was the equity of Hangzhou Tigermed Consulting Co compared to the previous year?

The equity of Hangzhou Tigermed Consulting Co has increased/decreased by 7.37% increased compared to the previous year.

What impact does a high equity have on investors of Hangzhou Tigermed Consulting Co?

A high equity is advantageous for investors of Hangzhou Tigermed Consulting Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Hangzhou Tigermed Consulting Co?

A low equity can be a risk for investors of Hangzhou Tigermed Consulting Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Hangzhou Tigermed Consulting Co affect the company?

An increase in equity of Hangzhou Tigermed Consulting Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Hangzhou Tigermed Consulting Co affect the company?

A reduction in equity of Hangzhou Tigermed Consulting Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Hangzhou Tigermed Consulting Co?

Some factors that can affect the equity of Hangzhou Tigermed Consulting Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Hangzhou Tigermed Consulting Co so important for investors?

The equity of Hangzhou Tigermed Consulting Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Hangzhou Tigermed Consulting Co take to change the equity?

To change equity, Hangzhou Tigermed Consulting Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Hangzhou Tigermed Consulting Co pay?

Over the past 12 months, Hangzhou Tigermed Consulting Co paid a dividend of 0.55 CNY . This corresponds to a dividend yield of about 0.8 %. For the coming 12 months, Hangzhou Tigermed Consulting Co is expected to pay a dividend of 0.6 CNY.

What is the dividend yield of Hangzhou Tigermed Consulting Co?

The current dividend yield of Hangzhou Tigermed Consulting Co is 0.8 %.

When does Hangzhou Tigermed Consulting Co pay dividends?

Hangzhou Tigermed Consulting Co pays a quarterly dividend. This is distributed in the months of July, June, August, August.

How secure is the dividend of Hangzhou Tigermed Consulting Co?

Hangzhou Tigermed Consulting Co paid dividends every year for the past 14 years.

What is the dividend of Hangzhou Tigermed Consulting Co?

For the upcoming 12 months, dividends amounting to 0.6 CNY are expected. This corresponds to a dividend yield of 0.87 %.

In which sector is Hangzhou Tigermed Consulting Co located?

Hangzhou Tigermed Consulting Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hangzhou Tigermed Consulting Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hangzhou Tigermed Consulting Co from 7/12/2024 amounting to 0.568 CNY, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did Hangzhou Tigermed Consulting Co pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Hangzhou Tigermed Consulting Co in the year 2023?

In the year 2023, Hangzhou Tigermed Consulting Co distributed 0.5 CNY as dividends.

In which currency does Hangzhou Tigermed Consulting Co pay out the dividend?

The dividends of Hangzhou Tigermed Consulting Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hangzhou Tigermed Consulting Co

Our stock analysis for Hangzhou Tigermed Consulting Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hangzhou Tigermed Consulting Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.